Search Results - "Neuschwander–Tetri, Brent A"

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites by Neuschwander‐Tetri, Brent A.

“…A significant body of evidence now forces us to rethink the causes of NASH. Once thought to be a disease caused by triglyceride accumulation in hepatocytes…”
Get full text

Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials by Brunt, Elizabeth M., Kleiner, David E., Wilson, Laura A., Sanyal, Arun J., Neuschwander‐Tetri, Brent A.

“…Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis that ultimately lead to cirrhosis in patients with nonalcoholic…”
Get full text

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis by Younossi, Zobair M., Loomba, Rohit, Anstee, Quentin M., Rinella, Mary E., Bugianesi, Elisabetta, Marchesini, Giulio, Neuschwander‐Tetri, Brent A., Serfaty, Lawrence, Negro, Francesco, Caldwell, Stephen H., Ratziu, Vlad, Corey, Kathleen E., Friedman, Scott L., Abdelmalek, Manal F., Harrison, Stephen A., Sanyal, Arun J., Lavine, Joel E., Mathurin, Philippe, Charlton, Michael R., Goodman, Zachary D., Chalasani, Naga P., Kowdley, Kris V., George, Jacob, Lindor, Keith

“…Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis…”
Get full text

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis by Younossi, Zobair M., Loomba, Rohit, Rinella, Mary E., Bugianesi, Elisabetta, Marchesini, Giulio, Neuschwander‐Tetri, Brent A., Serfaty, Lawrence, Negro, Francesco, Caldwell, Stephen H., Ratziu, Vlad, Corey, Kathleen E., Friedman, Scott L., Abdelmalek, Manal F., Harrison, Stephen A., Sanyal, Arun J., Lavine, Joel E., Mathurin, Philippe, Charlton, Michael R., Chalasani, Naga P., Anstee, Quentin M., Kowdley, Kris V., George, Jacob, Goodman, Zachary D., Lindor, Keith

“…Nonalcoholic fatty liver disease (NAFLD) and its progressive form non‐alcoholic steatohepatitis (NASH), are rapidly becoming among the top causes of cirrhosis,…”
Get full text

Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease by Vuppalanchi, Raj, Siddiqui, Mohammad S., Van Natta, Mark L., Hallinan, Erin, Brandman, Danielle, Kowdley, Kris, Neuschwander‐Tetri, Brent A., Loomba, Rohit, Dasarathy, Srinivas, Abdelmalek, Manal, Doo, Edward, Tonascia, James A., Kleiner, David E., Sanyal, Arun J., Chalasani, Naga

“…Vibration‐controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive…”
Get full text

NAFLD: Reporting Histologic Findings in Clinical Practice by Brunt, Elizabeth M., Kleiner, David E., Carpenter, Danielle H., Rinella, Mary, Harrison, Stephen A., Loomba, Rohit, Younossi, Zobair, Neuschwander‐Tetri, Brent A., Sanyal, Arun J.

“…The role of liver biopsy in NASH has evolved along with the increased recognition of the significance of this disease, and the unmet medical need it presents…”
Get full text

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science by Siddiqui, Mohammad Shadab, Harrison, Stephen A., Abdelmalek, Manal F., Anstee, Quentin M., Bedossa, Pierre, Castera, Laurent, Dimick‐Santos, Lara, Friedman, Scott L., Greene, Katherine, Kleiner, David E., Megnien, Sophie, Neuschwander‐Tetri, Brent A., Ratziu, Vlad, Schabel, Elmer, Miller, Veronica, Sanyal, Arun J.

“…Nonalcoholic steatohepatitis (NASH) is an important cause of liver‐related morbidity and mortality. There are no approved therapies, and the results of…”
Get full text

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings by Brunt, Elizabeth M., Kleiner, David E., Wilson, Laura A., Belt, Patricia, Neuschwander‐Tetri, Brent A.

“…The diagnosis of nonalcoholic steatohepatitis (NASH) is defined by the presence and pattern of specific histological abnormalities on liver biopsy. A separate…”
Get full text

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease by Kowdley, Kris V., Belt, Patricia, Wilson, Laura A., Yeh, Matthew M., Neuschwander-Tetri, Brent A., Chalasani, Naga, Sanyal, Arun J., Nelson, James E.

“…Serum ferritin (SF) levels are commonly elevated in patients with nonalcoholic fatty liver disease (NAFLD) because of systemic inflammation, increased iron…”
Get full text

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum by Cheung, Amanda, Neuschwander‐Tetri, Brent A., Kleiner, David E., Schabel, Elmer, Rinella, Mary, Harrison, Stephen, Ratziu, Vlad, Sanyal, Arun J., Loomba, Rohit, Jeannin Megnien, Sophie, Torstenson, Richard, Miller, Veronica

“…Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%‐2% of the population in developed…”
Get full text

The Importance of Glycemic Equipoise in NASH by Allen, Alina M., Neuschwander‐Tetri, Brent A.

Get full text

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients by Noureddin, Mazen, Yates, Katherine P., Vaughn, Ivana A., Neuschwander‐Tetri, Brent A., Sanyal, Arun J., McCullough, Arthur, Merriman, Raphael, Hameed, Bilal, Doo, Edward, Kleiner, David E., Behling, Cynthia, Loomba, Rohit

“…The characteristics of nonalcoholic fatty liver disease (NAFLD) in elderly patients are unknown. Therefore, we aimed to examine the differences between elderly…”
Get full text

The metabolic basis of nonalcoholic steatohepatitis by Chakravarthy, Manu V., Neuschwander‐Tetri, Brent A.

“…Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and is associated with significant morbidity and mortality worldwide, with a…”
Get full text

Relationship between three commonly used non‐invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non‐alcoholic steatohepatitis by Chalasani, Naga, Abdelmalek, Manal F., Loomba, Rohit, Kowdley, Kris V., McCullough, Arthur J., Dasarathy, Srinivasan, Neuschwander‐Tetri, Brent A., Terrault, Norah, Ferguson, Beatrice, Shringarpure, Reshma, Shapiro, David, Sanyal, Arun J., Tacke, Frank

“…Background & Aims Non‐invasive biomarkers are needed for monitoring changes in liver histology in patients with non‐alcoholic steatohepatitis (NASH)…”
Get full text

Too Much Sugar—The Not‐So‐Sweet Reality of Its Impact on Our Health by Neuschwander‐Tetri, Brent A., Corey, Kathleen E., Malhi, Harmeet

Get full text

Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association With Altered Regeneration and a Ductular Reaction by Richardson, Michelle M, Jonsson, Julie R, Powell, Elizabeth E, Brunt, Elizabeth M, Neuschwander–Tetri, Brent A, Bhathal, Prithi S, Dixon, John B, Weltman, Martin D, Tilg, Herbert, Moschen, Alexander R, Purdie, David M, Demetris, Anthony J, Clouston, Andrew D

“…Background & Aims: Portal fibrosis and linkage is a key feature of progressive disease in nonalcoholic steatohepatitis (NASH), but not simple steatosis. It is…”
Get full text

Mechanisms of NAFLD development and therapeutic strategies by Friedman, Scott L., Neuschwander-Tetri, Brent A., Rinella, Mary, Sanyal, Arun J.

“…There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome…”
Get full text

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease by Rinella, Mary E, Neuschwander-Tetri, Brent A, Siddiqui, Mohammad Shadab, Abdelmalek, Manal F, Caldwell, Stephen, Barb, Diana, Kleiner, David E, Loomba, Rohit

Get full text

Practice patterns in NAFLD and NASH: real life differs from published guidelines by Rinella, Mary E., Lominadze, Zurabi, Loomba, Rohit, Charlton, Michael, Neuschwander-Tetri, Brent A., Caldwell, Stephen H., Kowdley, Kris, Harrison, Stephen A.

“…Background: Management guidelines from the American Association for the Study of Liver Diseases/American College of Gastroenterology/American Gastroenterology…”
Get full text

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study by Charles, Edgar D., Neuschwander‐Tetri, Brent A., Pablo Frias, Juan, Kundu, Sudeep, Luo, Yi, Tirucherai, Giridhar S., Christian, Rose

“…Objective Obesity and type 2 diabetes mellitus (T2DM) are risk factors for nonalcoholic fatty liver disease, including nonalcoholic steatohepatitis. This study…”
Get full text